Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Cancer
Interventions: BIOLOGICAL: IMM-101|DRUG: Gemcitabine|DRUG: Nabpaclitaxel|DRUG: Capecitabine|DRUG: Folinic Acid|DRUG: Fluorouracil|DRUG: Irinotecan|DRUG: Oxaliplatin|BIOLOGICAL: cetuximab|BIOLOGICAL: Anti-PD1|BIOLOGICAL: Ipilimumab|DRUG: Cyclophosphamide
Sponsor: Immodulon Therapeutics Ltd